Wedbush Reiterates Outperform on Revolution Medicines, Maintains $147 Price Target

Benzinga Newsdesk www.benzinga.com Negative 65.8%

Neg 65.8% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll reiterates Revolution Medicines (NASDAQ:RVMD) with a Outperform and maintains $147 price target.